204
Participants
Start Date
March 26, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2027
AI-081
AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF.
NOT_YET_RECRUITING
The Tisch Cancer Institute, Mount Sinai Medical Center, New York
NOT_YET_RECRUITING
Columbia University Medical Center, New York
RECRUITING
University of North Carolina at Chapel Hill Cancer Center, Chapel Hill
RECRUITING
Prisma Health, Greenville
RECRUITING
University of Florida UF Health Cancer Center, Gainesville
RECRUITING
AdventHealth Cancer Institute, Orlando
NOT_YET_RECRUITING
Memorial Healthcare System, Hollywood
RECRUITING
Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala
NOT_YET_RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
Norton Cancer Center, Louisville
RECRUITING
The Ohio State University James Cancer Center, Columbus
RECRUITING
University of Michigan Rogel Cancer Center, Ann Arbor
NOT_YET_RECRUITING
Henry Ford Health, Detroit
NOT_YET_RECRUITING
Northwestern University, Chicago
RECRUITING
Highlands Oncology Group, Springdale
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
University of Utah Huntsman Cancer Institute, Salt Lake City
OncoC4, Inc.
INDUSTRY